Immuno-oncology Partnerships Portage's clinical-stage immuno-oncology focus, with a prior collaboration with Merck on PORT-2 for NSCLC and a recent LOI with Immunova, signals openness to co-development, licensing, or asset collaborations centered on iNKT-based therapies and IO combinations, creating opportunities for business development teams to propose joint programs.

Funding & Financing Needs With a private financing of 2.15 million completed in early 2025 and total funding around 6 million, Portage operates leanly and may value partnerships that provide funding, milestone-based structures, or grant-supported arrangements to de-risk development and accelerate timelines.

Development & Regulatory Readiness The relaunch of the adenosine subsidiary as an independent entity suggests a need for CMC, GMP manufacturing, IND enabling activities, and regulatory affairs support, presenting opportunities for outsourced development services and regulatory consulting to speed first-in-human timelines.

Lung Cancer Focus Active engagement in the European Lung Cancer Congress and focus on front-line or PD-1 refractory NSCLC indicate target markets for oncology CROs, trial sites with lung cancer expertise, and biomarker-enabled recruitment partnerships.

Leadership & Alliances Recent leadership changes and board additions expand Portage’s strategic network, offering openings to leverage connections for partnerships with academic groups, contract manufacturers, and strategic investors to advance asset development.